In contrast, JAK2 inhibitor, ruxolitinib, significantly suppressed tumor cells viability in the K-Ras mutant cancer cells, which indicates that JAK2-STAT3 signaling contributes to the drug resistance in this model. This evidence concerns the gene KRAS and neoplasm.